Video

Susan Melvin Hill on Supporting MPN Patients in Idaho

Susan Melvin Hill, patient advocate, discusses how she meets with and helps patients with myeloproliferative neoplasms (MPNs) in Idaho.

Susan Melvin Hill, patient advocate, discusses how she meets with and helps patients with myeloproliferative neoplasms (MPNs) in Idaho. Hill was named one of our 2015 MPN Heroes in the category of Commitment to the Broader MPN Community. Hill's journey began when she transitioned from myelofibrosis patient to dedicated patient advocate. In her dedication to help others with MPNs, Hill established Idaho’s first and only MPN support group. She currently mentors patients with MPNs in several states.

Hill continues to be involved in grassroots awareness activities. These include organizing the annual Rare Disease Day at the Idaho State Capitol, working to include MPN educational materials in the Leukemia & Lymphoma Society’s annual Light the Night Walk, supporting MPN Awareness Day with Governor’s Proclamations, and providing feedback on educational and patient advocacy materials for MPN publications. When she is not supporting MPN activities, Hill somehow finds the time to knit blankets for babies in the neonatal intensive care unit of her local hospital.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Waldenstrom macroglobulinemia is often slow growing, with high survival but lower quality of life over time, explained researcher Alisha Kimble.
Image of woman.
Image of two doctors and text.
Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss.
image of serzan.
Dr. Breelyn Wilky explains that personalized treatments are helping improve outcomes for patients with gastrointestinal stromal tumors.
Image of two doctors with text.
Image of doctors with text.
Treatment with zanzalintinib plus Opdivo and Opdualag is an option worth exploring in patients with previously untreated clear cell renal cell carcinoma
Image of two doctors and text.